Outlook Therapeutics, Inc. develops and commercializes ONS-5010/LYTENAVA, an ophthalmic formulation of bevacizumab for retina diseases, including wet age-related macular degeneration. Company news commonly covers the product’s European Commission and MHRA marketing authorizations, commercial launch activity in Germany, Austria and the UK, and U.S. regulatory communications involving the biologics license application pathway for neovascular AMD.
Updates also include capital-structure actions used to fund operations, such as public offerings, registered direct offerings, warrants, convertible-note amendments and note financing. Governance and shareholder-approval matters appear in connection with securities issuance and authorized-share requirements.
Outlook Therapeutics (Nasdaq: OTLK) announced that the FDA accepted its Formal Dispute Resolution Request (FDRR) for ONS-5010/LYTENAVA™ (bevacizumab-vikg) and granted a meeting with the deciding official in April 2026. The FDRR follows a December 30, 2025 Complete Response Letter and a March 2, 2026 Type A meeting.
Outlook cites Phase 3 NORSE TWO and NORSE EIGHT data that it says support efficacy and safety; the company reports no FDA safety concerns and notes a U.S. end-to-end manufacturing supply chain.
Outlook Therapeutics (Nasdaq: OTLK) closed a public offering on March 25, 2026, selling 20,000,000 shares of common stock together with warrants to purchase up to 20,000,000 shares at a combined public offering price of $0.25 per share and warrant.
The offering generated aggregate gross proceeds of $5.0 million before fees; the warrants have a $0.25 exercise price, are exercisable immediately and expire five years from issuance. The company intends to use net proceeds primarily for working capital and general corporate purposes.
Outlook Therapeutics (Nasdaq: OTLK) priced a public offering of 20,000,000 shares and accompanying warrants to buy 20,000,000 shares at a combined price of $0.25 per share/warrant, yielding aggregate gross proceeds of $5.0 million before fees.
Each warrant is exercisable immediately at $0.25 and expires five years from issuance; the offering is expected to close on or about March 25, 2026.
Outlook Therapeutics (Nasdaq: OTLK) announced on March 23, 2026 that it has commenced a best-efforts public offering of common stock (or pre-funded warrants) and accompanying warrants exercisable for common stock. The offering is subject to market and other conditions and may not be completed.
H.C. Wainwright is the exclusive placement agent. Net proceeds are intended primarily for working capital and general corporate purposes. The securities are offered under an effective Form S-3 shelf registration (File No. 333-278340); a prospectus supplement will be filed with the SEC.
Outlook Therapeutics (Nasdaq: OTLK) announced an amendment and a new financing on March 16, 2026. The company extended the Avondale convertible note maturity to Dec 31, 2026 and issued an $18.4 million non-convertible unsecured note to Atlas Sciences.
Outlook expects $17.0 million net proceeds after original issue discount, will use proceeds to pay down the Existing Note leaving ~$10.8 million of principal and interest, and the New Note matures on June 16, 2027 with interest = Prime + 3% (minimum 9.5% per annum).
Outlook Therapeutics (Nasdaq: OTLK) provided a regulatory update after a Type A meeting with the U.S. FDA regarding the Dec 30, 2025 Complete Response Letter for its BLA for ONS-5010/LYTENAVA (bevacizumab-vikg). The meeting focused on the FDA’s outstanding substantial-evidence issue and potential paths to approval.
NORSE TWO met its primary and key secondary endpoints with clinically meaningful, statistically significant visual-acuity improvements; NORSE EIGHT and other data were submitted as confirmatory evidence. The FDA identified no safety concerns. The company is evaluating regulatory options and continuing discussions to clarify confirmatory evidence and next steps toward potential U.S. approval.
Outlook Therapeutics (Nasdaq: OTLK) signed an exclusive commercial distribution agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland. Mediconsult will seek Marketing Authorization, import, distribute and commercialize LYTENAVA™, which Outlook will manufacture and supply.
LYTENAVA™ is expected to launch in Switzerland in 2027, subject to regulatory approval.
Outlook Therapeutics (Nasdaq: OTLK) reported Q1 FY2026 results and a regulatory update on Feb 17, 2026. The company recorded a $23.1M net loss ($0.38/share) and an adjusted net loss of $13.5M ($0.22/share). Unit sales of LYTENAVA more than doubled quarter-over-quarter and Austria launched in January 2026. A Type A meeting request was submitted to the FDA following a Dec 30, 2025 CRL for ONS-5010.
Outlook Therapeutics (Nasdaq: OTLK) submitted a Type A meeting request to the FDA on Feb 11, 2026 after receiving a Complete Response Letter (Dec 30, 2025) for its BLA for ONS-5010/LYTENAVA (bevacizumab-vikg) in wet AMD. The CRL cited a single deficiency alleging lack of substantial evidence of effectiveness and requested additional confirmatory evidence.
The company cites positive Phase 3 NORSE TWO results at 12 months, complementary data from NORSE EIGHT, mechanistic/pharmacodynamic evidence, favorable safety findings, and existing EU and UK marketing authorizations.
Outlook Therapeutics (Nasdaq: OTLK) on January 6, 2026 appointed Laura Cantrell as Vice President of Corporate Strategy and Business Development.
Ms. Cantrell brings more than 20 years of global biotechnology experience in corporate strategy, business development and portfolio leadership, and will lead strategic partnerships, licensing and corporate development initiatives as the company advances a differentiated ophthalmic formulation of bevacizumab.
Her background includes senior roles at Medivation (part of a team supporting a $14 billion acquisition by Pfizer), BeiGene, Sobi, Axovant Sciences, and Genentech/Roche; she holds an MBA from Emory and a BS in Biology from University of Michigan.